Natera, Inc. (NASDAQ:NTRA) Receives $160.63 Consensus Target Price from Analysts

Shares of Natera, Inc. (NASDAQ:NTRA) have earned an average rating of “Buy” from the seventeen research firms that are currently covering the company, MarketBeat Ratings reports. Seventeen investment analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued a report on the stock in the last year is $162.94.

Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. boosted their price target on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, December 13th. StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Piper Sandler lifted their price target on Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, November 18th. The Goldman Sachs Group increased their price objective on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. Finally, Leerink Partners lifted their target price on shares of Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th.

Insider Transactions at Natera

In other Natera news, insider John Fesko sold 669 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $159.60, for a total value of $106,772.40. Following the completion of the sale, the insider now owns 114,142 shares in the company, valued at approximately $18,217,063.20. This trade represents a 0.58 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gail Boxer Marcus sold 2,212 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $158.53, for a total value of $350,668.36. Following the sale, the director now owns 19,386 shares in the company, valued at approximately $3,073,262.58. This represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 249,940 shares of company stock worth $41,094,664. Insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in NTRA. Covestor Ltd grew its stake in shares of Natera by 34.3% in the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 95 shares during the period. Blue Trust Inc. raised its stake in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after acquiring an additional 97 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Natera by 32.7% during the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 106 shares during the period. Hanseatic Management Services Inc. lifted its holdings in shares of Natera by 12.0% during the fourth quarter. Hanseatic Management Services Inc. now owns 998 shares of the medical research company’s stock valued at $158,000 after acquiring an additional 107 shares during the period. Finally, Salem Investment Counselors Inc. grew its holdings in shares of Natera by 0.7% in the 4th quarter. Salem Investment Counselors Inc. now owns 16,280 shares of the medical research company’s stock worth $2,577,000 after purchasing an additional 110 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Stock Down 2.5 %

NASDAQ:NTRA opened at $167.61 on Thursday. The business’s fifty day moving average price is $166.20 and its 200 day moving average price is $136.25. The firm has a market capitalization of $22.13 billion, a price-to-earnings ratio of -95.23 and a beta of 1.65. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera has a 1-year low of $62.96 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA) last issued its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm’s quarterly revenue was up 63.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.95) EPS. On average, sell-side analysts forecast that Natera will post -1.56 earnings per share for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.